Global Viral Antigens 2026-2031 - Expanding Vaccine and Diagnostic Development Drives Market Growth
Dublin, Aug. 20, 2026 (GLOBE NEWSWIRE) -- The "Viral Antigens - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering.
Viral Antigens Market to Reach USD 361.2 Million by 2031, Expanding at an 11.2% CAGR
The global viral antigens market was valued at USD 191.6 million in 2025 and is projected to increase from USD 212.9 million in 2026 to USD 361.2 million by 2031. The market is expected to register a compound annual growth rate of 11.2% from 2026 through 2031, supported by expanding viral surveillance, rising diagnostic testing volumes, vaccine research and greater demand for standardized biological materials.
High-Throughput Viral Serology and Quality-Control Testing Drive Demand
Clinical laboratories have maintained elevated serology testing volumes as public health agencies continue post-pandemic surveillance and preparedness programs. This activity is generating recurring demand for standardized viral antigens used in diagnostic assays, proficiency testing, panel preparation and external quality assessment programs.
In January 2026, Microbix commercialized a recombinant SARS-CoV-2 nucleocapsid antigen for proficiency testing and external quality assessment applications in more than 30 countries. The integration of recombinant reference antigens into accredited quality programs can support durable supplier relationships, as replacing validated materials typically requires additional testing, documentation and internal review.
Seasonal and emerging viral threats are also increasing demand for high-throughput testing. At the same time, diagnostic developers are moving toward multiplex and syndromic panels that can identify multiple pathogens within a single workflow. These trends are creating opportunities for viral antigen suppliers with broad, well-characterized portfolios and dependable manufacturing capabilities.
Recombinant Viral Antigens Lead Market Growth
Recombinant antigens represented 32.8% of market revenue in 2025 and are forecast to expand at the fastest CAGR of 11.8% through 2031. Their market leadership reflects demand for batch consistency, purity, scalable manufacturing and greater control over antigen design. Diagnostic manufacturers also value the ability to target specific epitopes and generate reproducible assay performance for regulatory submissions.
Recombinant antigen platforms are increasingly important in vaccine development and pharmaceutical research, where precise antigen variants are required for binding studies, neutralization testing and assay control design. In March 2026, Sino Biological launched recombinant antigens for the 2026-2027 Northern Hemisphere influenza vaccine strains shortly after strain selection, demonstrating the commercial importance of rapid product development.
Production systems remain an important purchasing consideration. Bacterial expression platforms offer cost and speed advantages for simpler, non-glycosylated targets. Insect-cell and mammalian expression systems are preferred when native-like folding or glycosylation is required, particularly for enveloped virus proteins. Buyers are increasingly requesting multiple versions of the same antigen to support different assay stages and performance requirements.
Native antigens continue to serve validated serology workflows where conformational presentation is critical, including selected hepatitis and herpes simplex virus testing applications. Synthetic antigens are gaining adoption in peptide-based assays and rapid diagnostic tests, while inactivated and live attenuated formats remain important in vaccine development and specialized research.
Influenza Maintains the Largest Virus-Type Share
Influenza antigens accounted for 24.7% of viral antigens market revenue in 2025. Annual vaccine reformulation, ongoing clinical testing and antigenic drift create a dependable cycle of demand from laboratories, vaccine manufacturers and assay developers. Suppliers must rapidly update their product portfolios following official strain recommendations to remain competitive during each seasonal procurement cycle.
Coronavirus antigen demand is increasingly associated with surveillance, mucosal immunity research and proficiency testing rather than emergency purchasing. HIV and hepatitis antigens continue to benefit from screening programs, occupational health testing and blood bank workflows. The U.S. Food and Drug Administration's reclassification of qualitative hepatitis B virus antigen assays to Class II, effective October 2025, may also encourage additional diagnostic development.
Dengue is forecast to be the fastest-growing virus segment, registering an 11.6% CAGR through 2031. Growth is being supported by expanded surveillance, same-day testing requirements and public health initiatives in endemic regions. India's evaluation of broader NS1 rapid diagnostic test use illustrates the potential for lower-cost antigen-based formats to improve testing access at scale.
Cold-Chain Requirements and Validation Cycles Remain Key Challenges
Cold-chain dependence continues to affect native biological materials and temperature-sensitive recombinant products. Transportation deviations can reduce immunoreactivity, contribute to lot failures and disrupt downstream diagnostic kit manufacturing. These risks can also increase inventory costs as manufacturers maintain additional safety stock to protect against supply interruptions.
Market expansion may be further constrained by long validation cycles, a concentrated buyer base and increasingly rigorous requirements for analytical characterization, traceability and lot-release documentation. Suppliers with strong quality systems, reliable logistics and comprehensive technical files are therefore positioned to gain a competitive advantage in regulated accounts.
North America Leads as Asia-Pacific Records the Fastest Growth
North America held 39.6% of the global viral antigens market in 2025. The region benefits from extensive reference laboratory networks, established public health surveillance programs and a regulated in vitro diagnostics manufacturing industry. Demand in the United States is supported by strict requirements for traceability, reproducibility and technical documentation, while Canada and Mexico contribute through laboratory testing and infectious disease surveillance.
Europe remained the second-largest regional market, supported by advanced laboratory infrastructure, academic virology research and established diagnostic development hubs in Germany and the United Kingdom. Regulatory requirements favor suppliers capable of providing dependable quality systems, consistent manufacturing and robust product documentation.
Asia-Pacific is projected to record the fastest regional CAGR of 11.6% through 2031. Expanding dengue surveillance in India, Indonesia, Thailand and the Philippines, combined with growing biomanufacturing capacity in China and influenza monitoring in Japan, is strengthening regional demand. Competitive pricing, product stability and practical delivery timelines will remain important purchasing factors.
South America offers additional opportunities through public health laboratory networks and tropical disease testing, particularly in Brazil and Argentina. The Middle East and Africa remain developing markets, with demand concentrated in Gulf Cooperation Council healthcare systems and South Africa. Across emerging regions, affordable antigens with improved stability and less demanding logistics are expected to support broader market adoption.
Overall, the viral antigens market outlook remains positive as diagnostic testing, infectious disease surveillance, vaccine development and biomedical research continue to expand. Recombinant production platforms, rapid strain-specific product launches and broader antigen portfolios are expected to shape market growth through 2031.
Key Topics Covered:
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET LANDSCAPE
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Need for High-Throughput Viral Serology and QC Testing
4.2.2 Expansion of Recombinant Antigen Platforms for Diagnostics and Vaccine R and D
4.2.3 Growing Testing Volume for Seasonal and Emerging Viral Threats
4.2.4 Shift Toward Multiplex and Syndromic Viral Panels
4.2.5 Regulatory Push for Traceable and Well Characterized Reference Antigens
4.2.6 Growth of Outsourced Antigen Manufacturing and Custom Bioreagent Supply
4.3 Market Restraints
4.3.1 Batch Variability and Cold-Chain Sensitivity of Biological Inputs
4.3.2 Narrow Buyer Base and Long Validation Cycles in Diagnostics
4.3.3 Substitution Risk from Nucleic Acid and Protein-Free Assay Designs
4.3.4 Price Pressure in Commodity Antigen Catalog Products
4.4 Value Chain Analysis
4.5 Supply Chain Analysis
4.6 Regulatory Landscape
4.7 Technological Outlook
4.8 Porter's Five Forces Analysis
4.8.1 Bargaining Power of Suppliers
4.8.2 Bargaining Power of Buyers
4.8.3 Threat of New Entrants
4.8.4 Threat of Substitutes
4.8.5 Intensity of Competitive Rivalry
5 MARKET SIZE AND GROWTH FORECASTS
5.1 By Type
5.1.1 Native Antigens
5.1.2 Recombinant Antigens
5.1.3 Synthetic Antigens
5.1.4 Inactivated Antigens
5.1.5 Live Attenuated Antigens
5.1.6 Other Types
5.2 By Diagnostic Method
5.2.1 Antigen-Based Diagnostic Kits
5.2.2 Immunoassays
5.2.3 ELISA
5.2.4 Hemagglutination
5.2.5 Radioimmunoassay
5.2.6 Immunofluorescence
5.2.7 Immunoperoxidase Staining
5.2.8 Electron Microscopy
5.2.9 Other Diagnostic Methods
5.3 By Virus Type
5.3.1 Influenza Virus
5.3.2 Coronavirus
5.3.3 Human Immunodeficiency Virus
5.3.4 Hepatitis Virus
5.3.5 Herpes Simplex Virus
5.3.6 Dengue Virus
5.3.7 Zika Virus
5.3.8 Other Virus Types
5.4 By Application
5.4.1 Diagnostics
5.4.2 Vaccine Development
5.4.3 Research and Development
5.4.4 Therapeutic Use
5.4.5 Other Applications
5.5 By End User
5.5.1 Research and Diagnostic Laboratories
5.5.2 Pharmaceutical and Biotechnology Companies
5.5.3 Hospitals
5.5.4 Academic and Government Research Institutes
5.5.5 Veterinary Clinics
5.5.6 Other End Users
5.6 By Distribution Channel
5.6.1 Hospital Pharmacies
5.6.2 Retail Pharmacies
5.6.3 Online Pharmacies
5.7 Geography
5.7.1 North America
5.7.1.1 United States
5.7.1.2 Canada
5.7.1.3 Mexico
5.7.2 Europe
5.7.2.1 Germany
5.7.2.2 United Kingdom
5.7.2.3 France
5.7.2.4 Italy
5.7.2.5 Spain
5.7.2.6 Russia
5.7.2.7 Rest of Europe
5.7.3 Asia-Pacific
5.7.3.1 China
5.7.3.2 India
5.7.3.3 Japan
5.7.3.4 South Korea
5.7.3.5 Australia
5.7.3.6 Rest of Asia-Pacific
5.7.4 South America
5.7.4.1 Brazil
5.7.4.2 Argentina
5.7.4.3 Rest of South America
5.7.5 Middle East and Africa
5.7.5.1 GCC
5.7.5.2 South Africa
5.7.5.3 Rest of Middle East & Africa
6 COMPETITIVE LANDSCAPE
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Strategic Moves
6.4 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments)
6.4.1 Aalto Bio Reagents Ltd.
6.4.2 Abbott Laboratories
6.4.3 Becton, Dickinson and Company
6.4.4 bioMerieux SA
6.4.5 Bio-Rad Laboratories, Inc.
6.4.6 Bio-Techne Corporation
6.4.7 Cepheid
6.4.8 Creative Diagnostics
6.4.9 Danaher Corporation
6.4.10 DiaSorin S.p.A.
6.4.11 F. Hoffmann-La Roche Ltd
6.4.12 LGC Limited
6.4.13 Merck KGaA
6.4.14 Microbix Biosystems Inc.
6.4.15 ProSpec-Tany TechnoGene Ltd.
6.4.16 QuidelOrtho Corporation
6.4.17 Randox Laboratories Ltd.
6.4.18 Sino Biological, Inc.
6.4.19 The Native Antigen Company Ltd.
6.4.20 Thermo Fisher Scientific Inc.
7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK
7.1 White-Space and Unmet-Need Assessment
For more information about this report visit https://www.researchandmarkets.com/r/hwu17h
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.